Most Read Articles
Tristan Manalac, 6 days ago
Atopic dermatitis appears to impair sleep quality, but not sleep duration, in children, particularly in those with more severe diseases, according to a new study.
13 Mar 2019
Individuals following a diet low in or free of meat are at lower risk of diabetes, and this protective association is partly attributable to having a lower body mass index when compared with regular meat eaters, according to a study.
4 days ago
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation, a study has found.
13 Mar 2019
Vitamin E supplementation does not appear to contribute to blood pressure (BP) improvement, with results of a recent systematic review and meta-analysis showing decreases only in systolic (S)BP but no favourable effect on diastolic (D)BP and mean arterial pressure (MAP).

Extended propranolol use increases treatment success in high-risk infantile hemangioma

30 Aug 2018

Continuing treatment with oral propranolol beyond 6 months and up to 12 months appears to be effective in most patients with high-risk infantile hemangioma (IH), producing meaningful increases in treatment success, a study has shown.

The single-arm, open-label, phase III study included 43 infants aged 35–150 days with high-risk IH, who were initially treated with oral propranolol at 3 mg/kg per day for 6 months (initial treatment period [ITP]). If complete success was not achieved by 6 months, patients were retreated for up to 12 months of age (continuation period). Those who achieved success in the ITP were managed for 3 months without treatment (follow-up period). If rebound growth occurred during the follow-up period, treatment was reinitiated until success for 6 months maximum.

The primary outcome of treatment success after ITP was 47 percent. This number increased to 76 percent up to 12 months of age. Of the patients successfully treated, 68 percent sustained success for 3 months without treatment, with 24 percent requiring retreatment. Treatment success during the retreatment phase was documented in seven of eight patients.

Adverse events, which occurred in 80 percent of patients, were mild and consistent with known propranolol side effects.

The present data show that continuing propranolol treatment for up to 12 months of age effectively increases success rate in high-risk IH, with a satisfactory safety profile, researchers said.

To date, there is no consensus on the optimal duration of treatment with propranolol, which is used in the first-line setting, for IH. However, treatment up to 12 months of age has been proposed for those who do not fully respond to a 6-month course. [Sci Rep 2017;7:43292; J Plast Reconstr Aesthet Surg 2011;64:292-299; J Pediatr Surg 2012;47:707-714]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 6 days ago
Atopic dermatitis appears to impair sleep quality, but not sleep duration, in children, particularly in those with more severe diseases, according to a new study.
13 Mar 2019
Individuals following a diet low in or free of meat are at lower risk of diabetes, and this protective association is partly attributable to having a lower body mass index when compared with regular meat eaters, according to a study.
4 days ago
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation, a study has found.
13 Mar 2019
Vitamin E supplementation does not appear to contribute to blood pressure (BP) improvement, with results of a recent systematic review and meta-analysis showing decreases only in systolic (S)BP but no favourable effect on diastolic (D)BP and mean arterial pressure (MAP).